Sign up
Log in
MARKET
IMMX
IMMX
Immix Biopharma Inc
NASDAQ
2.240
+0.090
+4.19%
After Hours: 2.250 +0.01 +0.45% 19:49 07/26 EDT
OPEN
2.160
PREV CLOSE
2.150
HIGH
2.300
LOW
2.151
VOLUME
125.56K
TURNOVER
0
52 WEEK HIGH
7.75
52 WEEK LOW
1.550
MARKET CAP
59.17M
P/E (TTM)
-2.4182
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMMX last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at IMMX last week (0708-0712)?
Weekly Report · 07/15 11:59
Buy Rating Affirmed for Immix Biopharma Amid Promising NXC-201 Trial Outcomes and Market Potential
TipRanks · 07/09 10:16
Immix Biopharma doses first patient in U.S. AL amyloidosis trial
Immix Biopharma doses first patient in U.S. AL amyloidosis trial with NXC-201. Shares of IMMX dropped 7.20% to $2.19 during market hours. The company says the milestone is in-line with its mid-2024 guidance.
Seeking Alpha · 07/08 18:04
Immix Biopharma Doses First Patient In U.S. AL Amyloidosis Trial With CAR-T NXC-201; Data From ex-US Clinical Trial Reported At ASGCT 2024 Showed A 92% Overall Response Rate
1st patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a BCMA-targeted CAR-T cell therapy. Timing of milestone in-line with mid-2024 guidance. Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate.
Benzinga · 07/08 13:32
IMMIX BIOPHARMA INC - DATA FROM EX-US CLINICAL TRIAL REPORTED AT ASGCT 2024 SHOWED A 92% OVERALL RESPONSE RATE
Reuters · 07/08 13:31
Weekly Report: what happened at IMMX last week (0701-0705)?
Weekly Report · 07/08 12:02
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
Immix Biopharma, Inc. Announced the 1st patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy.
Barchart · 07/08 08:31
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.